Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Gutzmer, R; Wollenberg, A; Ugurel, S; Homey, B; Ganser, A; Kapp, A.
Cutaneous side effects of new antitumor drugs: clinical features and management.
Dtsch Arztebl Int. 2012; 109(8):133-140 Doi: 10.3238/arztebl.2012.0133 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Ugurel-Becker Selma
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Background: Many new antitumor drugs have been approved in recent years. Their side-effect profiles are distinct from those of older drugs, and their adverse effects are sometimes highly specific, particularly with respect to the skin. Methods: This article is based on articles retrieved by a selective search in Medline and the database of the American Society of Clinical Oncology (ASCO), as well as on the authors' personal experience. Results: Cutaneous adverse effects are among the more common adverse effects of new antitumor drugs: they occur in up to 34% of patients receiving multikinase inhibitors, up to 90% of those receiving selective tyrosine kinase inhibitors (such as EGFR or mutant BRAF inhibitors), and up to 68% of those receiving immuno-therapeutic agents (such as CTLA4 inhibitors). These adverse effects can be correlated with therapeutic benefit, but they can also be treatment-limiting because of their severity or visibility. Conclusion: The recognition and proper management of cutaneous adverse effects is an important part of treatment with new antitumor drugs.
Find related publications in this database (using NLM MeSH Indexing): Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use; CTLA-4 Antigen - antagonists and inhibitors; Cross-Sectional Studies -; Drug Eruptions - diagnosis Drug Eruptions - epidemiology Drug Eruptions - etiology; Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use; Humans -; Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use; Proto-Oncogene Proteins B-raf - antagonists and inhibitors; Receptor, Epidermal Growth Factor - antagonists and inhibitors; Treatment Outcome -